ArticleCancer medicine2026
Prognostic Value of Hemoglobin, Albumin, Lymphocyte, and Platelet Score in Locally Advanced Nasopharyngeal Carcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo investigate the prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in patients with locally advanced nasopharyngeal carcinoma (LANPC) receiving concurrent chemoradiotherapy (CCRT), and to clarify its predictive significance for overall survival (OS), progression-free survival (PFS), locoregional failure-free survival (LRFFS), and distant metastasis-free survival (DMFS).
methodsClinical data of 295 patients with LANPC who received CCRT between April 2021 and April 2022 were retrospectively analyzed. Routine blood and biochemical indices were collected within 1 week before CCRT. The HALP score was calculated as follows: HALP = [hemoglobin (g/L) × albumin (g/L) × lymphocytes (10
resultsSurvival analysis showed that the 3-year OS of the high and low HALP groups were 95.27% and 93.20%, the 3-year PFS were 87.84% and 74.15%, and the 3-year DMFS were 87.84% and 78.91%, respectively. The differences between the groups were statistically significant (p < 0.05). While the 3-year LRFFS were 97.30% vs. 96.60%, there were no statistically significant differences between the groups. Multivariate Cox regression analysis confirmed that a low HALP score was an independent risk factor for OS and PFS.
conclusionThe HALP group is an effective predictor of prognosis in patients with LANPC. A low HALP group indicated higher disease progression and death. This measurement can be used for prognostic stratification and individualized treatment decision-making, both simply and economically, and provides a reference for clinical decision-making and individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.